Compare VanEck Junior Gold Miners (GDXJ) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Gilead Sciences, Inc. — how do they compare? VanEck Junior Gold Miners trades at $92.54, while Gilead Sciences, Inc. trades at $135.36 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while VanEck Junior Gold Miners pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals.
| GDXJ | GILD | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $155.80 |
52-Week Low | $64.22 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ is trading at $92.16, down 6.31% over the past 24 hours amid bearish technical signals. The ETF shows weakness with moving averages indicating strong selling pressure while oscillators remain neutral. Recent news highlights GDXJ's underperformance compared to peers and questions about its small-cap exposure composition.
The outlook remains cautious with technical indicators favoring sellers and fundamental concerns about portfolio composition. Investment opportunities exist for contrarian investors betting on gold miner recovery, but risks include continued underperformance and market volatility. The bearish technical setup suggests near-term pressure may persist.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
